|Bid||16.01 x 3200|
|Ask||19.33 x 900|
|Day's Range||18.90 - 19.84|
|52 Week Range||7.12 - 23.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a market capitalization of US$2.06B, rarely draw their attention from the investingRead More...
Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.
On a per-share basis, the Henderson, Nevada-based company said it had a loss of 16 cents. Losses, adjusted for one-time gains and costs, came to 15 cents per share. The biotechnology company posted revenue ...
Small-cap stocks are considered riskier than large caps or even mid caps. Of course, this means that smaller stocks have greater potential to make profits for investors. This does not mean that you should buy risky stocks randomly.
It was a busy week last week in the biotechnology space, with a whole host of companies putting out updates on their respective operations (primarily rooted in development pipelines) and these updates subsequently injecting a considerable amount of volatility into the markets on their release. Here’s a look at some of the biggest movers, what […] The post Here’s What Happened Last Week In Biotech appeared first on Market Exclusive.
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
Spectrum Pharmaceuticals (SPPI) needs investors to pay close attention to the stock based on moves in the options market lately.
Maxim raises BeiGene Ltd (NASDAQ: BGNE ) price target from $160 to $200; Says the company continues to advance its clinical pipeline with multiple catalysts ahead and a strong balance sheet with runway ...
Surging implied volatility makes Spectrum Pharmaceuticals (SPPI) stock lucrative to the option traders.
Spectrum (SPPI) reports narrower-than-expected loss in the fourth quarter, while it misses on revenues. Rolontis successful in phase III study.
The Henderson, Nevada-based company said it had a loss of 29 cents per share. The biotechnology company posted revenue of $28.6 million in the period. For the year, the company reported that its loss widened ...